PURPOSE: Broad panel sequencing of tumors facilitates routine care of people with cancer as well as clinical trial matching for novel genome-directed therapies. We sought to extend the use of broad panel sequencing results to survival stratification and clinical outcome prediction. PATIENTS AND METHODS: Using sequencing results from a cohort of 1,054 patients with advanced lung adenocarcinomas, we developed OncoCast, a machine learning tool for survival risk stratification and biomarker identification. RESULTS: With OncoCast, we stratified this patient cohort into four risk groups based on tumor genomic profile. Patients whose tumors harbored a high-risk profile had a median survival of 7.3 months (95% CI 5.5-10.9), compared to a low risk group with a median survival of 32.8 months (95% CI 26.3-38.5), with a hazard ratio of 4.6 (P<2e-16), far superior to any individual gene predictor or standard clinical characteristics. We found that co-mutations of both STK11 and KEAP1 are a strong determinant of unfavorable prognosis with currently available therapies. In patients with targetable oncogenes including EGFR/ALK/ROS1 and received targeted therapies, the tumor genetic background further differentiated survival with mutations in TP53 and ARID1A contributing to a higher risk score for shorter survival. CONCLUSION: Mutational profile derived from broad-panel sequencing presents an effective genomic stratification for patient survival in advanced lung adenocarcinoma. OncoCast is available as a public resource that facilitates the incorporation of mutational data to predict individual patient prognosis and compare risk characteristics of patient populations.
PURPOSE: Broad panel sequencing of tumors facilitates routine care of people with cancer as well as clinical trial matching for novel genome-directed therapies. We sought to extend the use of broad panel sequencing results to survival stratification and clinical outcome prediction. PATIENTS AND METHODS: Using sequencing results from a cohort of 1,054 patients with advanced lung adenocarcinomas, we developed OncoCast, a machine learning tool for survival risk stratification and biomarker identification. RESULTS: With OncoCast, we stratified this patient cohort into four risk groups based on tumor genomic profile. Patients whose tumors harbored a high-risk profile had a median survival of 7.3 months (95% CI 5.5-10.9), compared to a low risk group with a median survival of 32.8 months (95% CI 26.3-38.5), with a hazard ratio of 4.6 (P<2e-16), far superior to any individual gene predictor or standard clinical characteristics. We found that co-mutations of both STK11 and KEAP1 are a strong determinant of unfavorable prognosis with currently available therapies. In patients with targetable oncogenes including EGFR/ALK/ROS1 and received targeted therapies, the tumor genetic background further differentiated survival with mutations in TP53 and ARID1A contributing to a higher risk score for shorter survival. CONCLUSION: Mutational profile derived from broad-panel sequencing presents an effective genomic stratification for patient survival in advanced lung adenocarcinoma. OncoCast is available as a public resource that facilitates the incorporation of mutational data to predict individual patient prognosis and compare risk characteristics of patient populations.
Entities:
Keywords:
Metastatic lung adenocarcinoma; mutational profiling; prognostic model
Authors: Heinz-Josef Klümpen; Karla C S Queiroz; C Arnold Spek; Carel J M van Noesel; Helmy C Brink; Wendy W J de Leng; Roeland F de Wilde; Elisabeth M H Mathus-Vliegen; G Johan A Offerhaus; Maarten A Alleman; Anneke M Westermann; Dirk J Richel Journal: J Clin Oncol Date: 2010-12-28 Impact factor: 44.544
Authors: Mark G Kris; Bruce E Johnson; Lynne D Berry; David J Kwiatkowski; A John Iafrate; Ignacio I Wistuba; Marileila Varella-Garcia; Wilbur A Franklin; Samuel L Aronson; Pei-Fang Su; Yu Shyr; D Ross Camidge; Lecia V Sequist; Bonnie S Glisson; Fadlo R Khuri; Edward B Garon; William Pao; Charles Rudin; Joan Schiller; Eric B Haura; Mark Socinski; Keisuke Shirai; Heidi Chen; Giuseppe Giaccone; Marc Ladanyi; Kelly Kugler; John D Minna; Paul A Bunn Journal: JAMA Date: 2014-05-21 Impact factor: 56.272
Authors: Dongmei Ren; Nicole F Villeneuve; Tao Jiang; Tongde Wu; Alexandria Lau; Henry A Toppin; Donna D Zhang Journal: Proc Natl Acad Sci U S A Date: 2011-01-04 Impact factor: 11.205
Authors: Kerby Shedden; Jeremy M G Taylor; Steven A Enkemann; Ming-Sound Tsao; Timothy J Yeatman; William L Gerald; Steven Eschrich; Igor Jurisica; Thomas J Giordano; David E Misek; Andrew C Chang; Chang Qi Zhu; Daniel Strumpf; Samir Hanash; Frances A Shepherd; Keyue Ding; Lesley Seymour; Katsuhiko Naoki; Nathan Pennell; Barbara Weir; Roel Verhaak; Christine Ladd-Acosta; Todd Golub; Michael Gruidl; Anupama Sharma; Janos Szoke; Maureen Zakowski; Valerie Rusch; Mark Kris; Agnes Viale; Noriko Motoi; William Travis; Barbara Conley; Venkatraman E Seshan; Matthew Meyerson; Rork Kuick; Kevin K Dobbin; Tracy Lively; James W Jacobson; David G Beer Journal: Nat Med Date: 2008-07-20 Impact factor: 53.440
Authors: D E Gerber; S E Dahlberg; A B Sandler; D H Ahn; J H Schiller; J R Brahmer; D H Johnson Journal: Br J Cancer Date: 2013-08-13 Impact factor: 7.640
Authors: Elza C de Bruin; Nicholas McGranahan; Richard Mitter; Max Salm; David C Wedge; Lucy Yates; Mariam Jamal-Hanjani; Seema Shafi; Nirupa Murugaesu; Andrew J Rowan; Eva Grönroos; Madiha A Muhammad; Stuart Horswell; Marco Gerlinger; Ignacio Varela; David Jones; John Marshall; Thierry Voet; Peter Van Loo; Doris M Rassl; Robert C Rintoul; Sam M Janes; Siow-Ming Lee; Martin Forster; Tanya Ahmad; David Lawrence; Mary Falzon; Arrigo Capitanio; Timothy T Harkins; Clarence C Lee; Warren Tom; Enock Teefe; Shann-Ching Chen; Sharmin Begum; Adam Rabinowitz; Benjamin Phillimore; Bradley Spencer-Dene; Gordon Stamp; Zoltan Szallasi; Nik Matthews; Aengus Stewart; Peter Campbell; Charles Swanton Journal: Science Date: 2014-10-10 Impact factor: 47.728
Authors: Kathryn C Arbour; Hira Rizvi; Andrew J Plodkowski; Matthew D Hellmann; Andrea Knezevic; Glenn Heller; Helena A Yu; Marc Ladanyi; Mark G Kris; Maria E Arcila; Charles M Rudin; Piro Lito; Gregory J Riely Journal: Clin Cancer Res Date: 2021-02-08 Impact factor: 12.531
Authors: Charles M Rudin; Alvaro Quintanal-Villalonga; Hirokazu Taniguchi; Yingqian A Zhan; Maysun M Hasan; Shweta S Chavan; Fanli Meng; Fathema Uddin; Viola Allaj; Parvathy Manoj; Nisargbhai S Shah; Joseph M Chan; Metamia Ciampricotti; Andrew Chow; Michael Offin; Jordana Ray-Kirton; Jacklynn D Egger; Umesh K Bhanot; Irina Linkov; Marina Asher; Michael H Roehrl; Katia Ventura; Juan Qiu; Elisa de Stanchina; Jason C Chang; Natasha Rekhtman; Brian Houck-Loomis; Richard P Koche; Helena A Yu; Triparna Sen Journal: J Hematol Oncol Date: 2021-10-16 Impact factor: 17.388
Authors: A J Schoenfeld; H Rizvi; C Bandlamudi; J L Sauter; W D Travis; N Rekhtman; A J Plodkowski; R Perez-Johnston; P Sawan; A Beras; J V Egger; M Ladanyi; K C Arbour; C M Rudin; G J Riely; B S Taylor; M T A Donoghue; M D Hellmann Journal: Ann Oncol Date: 2020-02-06 Impact factor: 32.976
Authors: Jamie E Chaft; Patrick M Forde; Joshua E Reuss; Valsamo Anagnostou; Tricia R Cottrell; Kellie N Smith; Franco Verde; Marianna Zahurak; Mara Lanis; Joseph C Murray; Hok Yee Chan; Caroline McCarthy; Daphne Wang; James R White; Stephen Yang; Richard Battafarano; Stephen Broderick; Errol Bush; Malcolm Brock; Jinny Ha; David Jones; Taha Merghoub; Janis Taube; Victor E Velculescu; Gary Rosner; Peter Illei; Drew M Pardoll; Suzanne Topalian; Jarushka Naidoo; Ben Levy; Matthew Hellmann; Julie R Brahmer Journal: J Immunother Cancer Date: 2020-09 Impact factor: 13.751
Authors: Sarah F McGough; Devin Incerti; Svetlana Lyalina; Ryan Copping; Balasubramanian Narasimhan; Robert Tibshirani Journal: Stat Med Date: 2021-07-24 Impact factor: 2.497